Cited by 17Virus-based gene therapy researchLysosomal Storage Disorders ResearchRNA Interference and Gene Delivery

Gene therapy for the leukodystrophies: From preclinical animal studies to clinical trials.

Open access
Metovic, Jasna, Li, Yedda, Gong, Yi, Eichler, Florian·2024·Neurotherapeutics

Abstract

Leukodystrophies are progressive single gene disorders affecting the white matter of the brain. Several gene therapy trials are in progress to address the urgent unmet need for this patient population. We performed a comprehensive literature review of all gene therapy clinical trials listed in www.clinicaltrials.gov through August 2024, and the relevant preclinical studies that enabled clinical translation. Of the approximately 50 leukodystrophies described to date, only eight have existing gene therapy clinical trials: metachromatic leukodystrophy, X-linked adrenoleukodystrophy, globoid cell leukodystrophy, Canavan disease, giant axonal neuropathy, GM2 gangliosidoses, Alexander disease and Pelizaeus-Merzbacher disease. What led to the emergence of gene therapy trials for these specific disorders? What preclinical data or disease context was enabling? For each of these eight disorders, we first describe its pathophysiology and clinical presentation. We discuss the impact of gene therapy delivery route, targeted cell type, delivery modality, dosage, and timing on therapeutic efficacy. We note that use of allogeneic hematopoietic stem cell transplantation in some leukodystrophies allowed for an accelerated path to clinic even in the absence of available animal models. In other leukodystrophies, small and large animal model studies enabled clinical translation of experimental gene therapies. Human clinical trials for the leukodystrophies include ex vivo lentiviral gene delivery, in vivo AAV-mediated gene delivery, and intrathecal antisense oligonucleotide approaches. We outline adverse events associated with each modality focusing specifically on genotoxicity and immunotoxicity. We review monitoring and management of events related to insertional mutagenesis and immune responses. The data presented in this review show that gene therapy, while promising, requires systematic monitoring to account for the precarious disease biology and the adverse events associated with new technology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neurot.2024.e00443

Cites

236 of 238 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Current advances in treatment options for leukodystrophies may also benefit the treatment of ACBD5 patients.

    “Although its relevance to ACBD5 deficiency remains to be established, current advances in the treatment options for leukodystrophies may also benefit the treatment of ACBD5 patients (Metovic et al., 2024; Wolf et al., 2025).”

    From The neurological pathology of peroxisomal ACBD5 deficiency – lessons from patients and mouse models (2025) · cites this paper as Metovic et al., 2024

    The Future directions section (page not supplied) describes advances in leukodystrophy gene therapies and delivery technologies. It does not address ACBD5 deficiency or establish that these advances could benefit ACBD5 patients; it says benefits and risks must be evaluated in a disease-specific context. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [188]Kuhn J. Cascella M. Alexander disease. StatPearls, treasure island (FL) 2024 StatPearls Publishing 32965913

Cited by

Sorted by citations

Authors
Metovic, J., Li, Y., Gong, Y., & Eichler, F.
Affiliations
Harvard University (US)
Corresponding author
Eichler, Florian
Venue
Neurotherapeutics
Publisher
Elsevier BV
Published
2024-07
Volume
21
Issue
4
Pages
e00443
ISSN
1878-7479 (ISSN-L)
OpenAlex
W4402509692
Cited by
16
References
237
Citations by year
2026: 7 · 2025: 8 · 2024: 1
FWCI
1.10
Type
journal article
Language
en
Open access
Locations
  • Neurotherapeutics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
National Institute of Neurological Disorders and Stroke (R01NS082331, R01NS072446, U54NS115052)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Physiology › Lysosomal Storage Disorders Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
leukodystrophy, gene therapy, clinical trials, animal models, metachromatic leukodystrophy, X-linked adrenoleukodystrophy, Krabbe disease, Canavan disease, giant axonal neuropathy, GM2 gangliosidoses, Alexander disease, Pelizaeus-Merzbacher disease, lentiviral gene delivery, AAV gene delivery, antisense oligonucleotides, hematopoietic stem cell transplantation, insertional mutagenesis, genotoxicity, immunotoxicity, white matter disease
MeSH terms
Animals, Clinical Trials as Topic, Disease Models, Animal, Humans, Genetic Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review